Literature DB >> 17145217

Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl.

William C Cromwell1, James D Otvos.   

Abstract

Patients with type 2 diabetes mellitus have an increased risk of cardiovascular events even when treated to low-density lipoprotein (LDL) cholesterol goals. The purpose of this study was to determine how many diabetic patients with low LDL cholesterol have correspondingly low numbers of LDL particles (LDL-P) and the extent to which those achieving target levels of LDL cholesterol and non-high-density lipoprotein (HDL) cholesterol might still harbor residual risk associated with increased LDL-P. Split-sample measurements of LDL cholesterol, non-HDL cholesterol, and nuclear magnetic resonance measured LDL-P were performed on plasma samples from 2,355 patients with type 2 diabetes seen in clinical practice and who had LDL cholesterol levels &lt;100 mg/dl. Substantial heterogeneity of LDL-P was noted among patients with low or very low levels of LDL cholesterol. Of 1,484 patients with low LDL cholesterol (70 to 99 mg/dl), only 385 (25.9%) had low levels of LDL-P (&lt;20th percentile of an ethnically diverse contemporary reference population), whereas 468 (31.6%) had LDL-P values >50th percentile (>1,300 nmol/L). Among the 871 patients with very low LDL cholesterol, i.e., &lt;70 mg/dl, 349 (40.1%) had LDL-P levels >1,000 nmol/L (>20th percentile) and 91 (10.4%) had LDL-P levels >50th percentile. For patients with high triglyceride values (200 to 400 mg/dl), there was less discordance between LDL-P and non-HDL cholesterol than between LDL-P and LDL cholesterol. However, for those with triglyceride levels &lt;200 mg/dl, LDL-P distributions were similarly wide for patients having achieved low or very low targets of LDL cholesterol or non-HDL cholesterol. In conclusion, these data demonstrate that patients with type 2 diabetes mellitus and LDL cholesterol levels &lt;100 mg/dl are extremely heterogeneous with regard to LDL-P and, by inference, LDL-based cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17145217     DOI: 10.1016/j.amjcard.2006.07.036

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  22 in total

1.  Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies.

Authors:  Robert S Rosenson; Bertram Pitt
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-12-17

Review 2.  Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease.

Authors:  William C Cromwell; Thomas A Barringer
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

Review 3.  Cardiovascular risk assessment and screening in diabetes.

Authors:  Yanglu Zhao
Journal:  Cardiovasc Endocrinol       Date:  2017-02-15

4.  Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study.

Authors:  Salim S Virani; Diane J Catellier; Lisa A Pompeii; Vijay Nambi; Ron C Hoogeveen; Bruce A Wasserman; Josef Coresh; Thomas H Mosley; James D Otvos; A Richey Sharrett; Eric Boerwinkle; Christie M Ballantyne
Journal:  Atherosclerosis       Date:  2011-08-07       Impact factor: 5.162

Review 5.  The evolution and refinement of traditional risk factors for cardiovascular disease.

Authors:  Emil M deGoma; Joshua W Knowles; Fabio Angeli; Matthew J Budoff; Daniel J Rader
Journal:  Cardiol Rev       Date:  2012 May-Jun       Impact factor: 2.644

6.  LDL particle size and number compared with LDL cholesterol and risk categorization in end-stage renal disease patients.

Authors:  Rodney G Bowden; Ronald L Wilson; A Alexander Beaujean
Journal:  J Nephrol       Date:  2011 Nov-Dec       Impact factor: 3.902

Review 7.  Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition.

Authors:  Paul D Rosenblit
Journal:  Curr Diab Rep       Date:  2019-07-22       Impact factor: 4.810

8.  Discordance between non-HDL-cholesterol and LDL-particle measurements: results from the Multi-Ethnic Study of Atherosclerosis.

Authors:  Emil M Degoma; Mat D Davis; Richard L Dunbar; Emile R Mohler; Philip Greenland; Benjamin French
Journal:  Atherosclerosis       Date:  2013-03-26       Impact factor: 5.162

9.  LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management.

Authors:  William C Cromwell; James D Otvos; Michelle J Keyes; Michael J Pencina; Lisa Sullivan; Ramachandran S Vasan; Peter W F Wilson; Ralph B D'Agostino
Journal:  J Clin Lipidol       Date:  2007-12       Impact factor: 4.766

10.  Intravascular ultrasound morphology of culprit lesions and clinical demographics in patients with acute coronary syndrome in relation to low-density lipoprotein cholesterol levels at onset.

Authors:  Naoko Takaoka; Kenichi Tsujita; Koichi Kaikita; Seiji Hokimoto; Kenshi Yamanaga; Naohiro Komura; Tadasuke Chitose; Takamichi Ono; Michio Mizobe; Eiji Horio; Koji Sato; Naoki Nakayama; Michiyo Saito; Satomi Iwashita; Sunao Kojima; Shinji Tayama; Seigo Sugiyama; Sunao Nakamura; Hisao Ogawa
Journal:  Heart Vessels       Date:  2013-08-28       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.